Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 4, 2011, Pages 245-253

  Catalan V ^a,b   Gomez Ambrosi J ^a,b   Rodriguez A ^a,b   Ramirez B ^a,b   Silva, C ^a,b   Rotellar, F ^a,b   Cienfuegos, J A ^a,b   Salvador, J ^a,b   Fruhbeck G ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Fatty liver disease; Gene expression; Inflammation; Lipid metabolism; NAMPT; Obesity; Peripheral blood cells

Indexed keywords

AUTACOID; CYTOKINE; LIPID; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; BIOPSY; BLOOD; BLOOD CELL; BODY MASS; DYSLIPIDEMIA; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTRAABDOMINAL FAT; LIVER; MALE; METABOLISM; MIDDLE AGED; MORBID OBESITY; OBESITY; PATHOPHYSIOLOGY;

ADIPOSITY; ADULT; BIOPSY; BLOOD CELLS; BODY MASS INDEX; CYTOKINES; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; LIPIDS; LIVER; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; RNA, MESSENGER;

EID: 79952702085     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.09.008     Document Type: Article

References (63)

1. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:367-377.
2. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
3. Tilg H., Hotamisligil G.S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945.
4. Frühbeck G., Gómez-Ambrosi J. Rationale for the existence of additional adipostatic hormones. FASEB J 2001, 15:1996-2006.
5. Fortuño A., Rodríguez A., Gómez-Ambrosi J., Frühbeck G., Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59:51-60.
6. Badman M.K., Flier J.S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132:2103-2115.
7. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002, 32:3225-3234.
8. Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004, 279:50754-50756.
9. Sommer G., Garten A., Petzold S., Beck-Sickinger A.G., Bluher M., Stumvoll M., et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci 2008, 115:13-23.
10. Revollo J.R., Grimm A.A., Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007, 23:164-170.
11. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-1437.
12. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113:1318-1327.
13. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
14. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
15. Arner P. Visfatin-a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:28-30.
16. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
17. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Retraction. Science 2007, 318:565.
18. de Luis DA, Sagrado MG, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle. Nutrition, in press. doi:10.1016/j.nutr.2008.11.019.
19. Varma V., Yao-Borengasser A., Rasouli N., Bodles A.M., Phanavanh B., Lee M.J., et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007, 92:666-672.
20. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
21. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:295-299.
22. López-Bermejo A., Chico-Julia B., Fernández-Balsells M., Recasens M., Esteve E., Casamitjana R., et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes 2006, 55:2871-2875.
23. Hammarstedt A., Pihlajamaki J., Rotter Sopasakis V., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006, 91:1181-1184.
24. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91:3165-3170.
25. Ingelsson E., Larson M.G., Fox C.S., Yin X., Wang T.J., Lipinska I., et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007, 30:1278-1280.
26. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 14:222-231.
27. Busso N., Karababa M., Nobile M., Rolaz A., Van Gool F., Galli M., et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 2008, 3:e2267.
28. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
29. Oki K., Yamane K., Kamei N., Nojima H., Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 2007, 67:796-800.
30. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007, 178:1748-1758.
31. Seo J.A., Jang E.S., Kim B.G., Ryu O.H., Kim H.Y., Lee K.W., et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2008, 79:108-111.
32. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci 2008, 114:275-288.
33. Trayhurn P., Wang B., Wood I.S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?. Br J Nutr 2008, 100:227-235.
34. Hosogai N., Fukuhara A., Oshima K., Miyata Y., Tanaka S., Segawa K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
35. Rausch M.E., Weisberg S., Vardhana P., Tortoriello D.V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes 2008, 32:451-463.
36. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70:1469-1480.
37. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110:1564-1571.
38. Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004, 89:5043-5047.
39. Samara A., Pfister M., Marie B., Visvikis-Siest S. Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol 2008, 69:568-574.
40. Sheu W.H., Chang T.M., Lee W.J., Ou H.C., Wu C.M., Tseng L.N., et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity 2008, 16:1033-1038.
41. Das S.K., Roberts S.B., Kehayias J.J., Wang J., Hsu L.K., Shikora S.A., et al. Body composition assessment in extreme obesity and after massive weight loss induced by gastric bypass surgery. Am J Physiol Endocrinol Metab 2003, 284:E1080-E1088.
42. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
43. Catalán V., Gómez-Ambrosi J., Rodríguez A., Ramírez B., Silva C., Rotellar F., et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med 2009, 87:803-813.
44. Korner A., Garten A., Bluher M., Tauscher R., Kratzsch J., Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007, 92:4783-4791.
45. Retnakaran R., Youn B.S., Liu Y., Hanley A.J., Lee N.S., Park J.W., et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol 2008, 69:885-893.
46. Tsiotra P.C., Tsigos C., Yfanti E., Anastasiou E., Vikentiou M., Psarra K., et al. Visfatin, TNF-α and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007, 39:758-763.
47. Filippatos T.D., Derdemezis C.S., Kiortsis D.N., Tselepis A.D., Elisaf M.S. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007, 30:323-326.
48. Sun G., Bishop J., Khalili S., Vasdev S., Gill V., Pace D., et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007, 85:399-404.
49. Zhong M., Tan H.W., Gong H.P., Wang S.F., Zhang Y., Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 2008, 69:878-884.
50. Wang P., van Greevenbroek M.M., Bouwman F.G., Brouwers M.C., van der Kallen C.J., Smit E., et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflügers Arch 2007, 454:971-976.
51. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
52. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
53. Aller R., de Luis D.A., Izaola O., Sagrado M.G., Conde R., Velasco M.C., et al. Influence of Visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2008, 54:1772-1777.
54. Hara N., Yamada K., Shibata T., Osago H., Hashimoto T., Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007, 282:24574-24582.
55. Deng X.Q., Chen L.L., Li N.X. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007, 27:708-715.
56. You M., Cao Q., Liang X., Ajmo J.M., Ness G.C. Mammalian sirtuin 1 is involved in the protective action of dietary saturated fat against alcoholic fatty liver in mice. J Nutr 2008, 138:497-501.
57. Malavazos A.E., Ermetici F., Cereda E., Coman C., Locati M., Morricone L., et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 2008, 18:523-530.
58. Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
59. Zhang Y.Y., Gottardo L., Thompson R., Powers C., Nolan D., Duffy J., et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity 2006, 14:2119-2126.
60. Bae S.K., Kim S.R., Kim J.G., Kim J.Y., Koo T.H., Jang H.O., et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006, 580:4105-4113.
61. Segawa K., Fukuhara A., Hosogai N., Morita K., Okuno Y., Tanaka M., et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism. Biochem Biophys Res Commun 2006, 349:875-882.
62. Wang B., Wood I.S., Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflügers Arch 2007, 455:479-492.
63. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118-E1128.